Adagio Medical Holdings, Inc. is a medical device company developing and placing on the European Union (EU) market ablation technologies for the treatment of cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. Its product portfolio consists of three product families: iCLAS atrial ULTC catheter and accessories, vCLAS ventricular ULTC catheter, and Cryopulse atrial PFCA catheter and accessories. All of these catheters share the same ULTC cryoablation console. A standalone PFA console connected to a cryoablation console for PFCA treatment synchronization is used in conjunction with Cryopulse catheter. The iCLAS system is CE-marked with the indication for treatment of paroxysmal atrial fibrillation, persistent atrial fibrillation and atrial flutter. The vCLAS ventricular catheter has been specifically designed for treatment of the ventricular arrhythmia. Its product offerings consist largely of the single use ablation catheters and consoles.
企業コードADGM
会社名Adagio Medical Holdings Inc
上場日Feb 26, 2021
最高経営責任者「CEO」Mr. Todd Usen
従業員数86
証券種類Ordinary Share
決算期末Feb 26
本社所在地26051 Merit Circle
都市LAGUNA HILLS
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号92653
電話番号12122842300
ウェブサイト
企業コードADGM
上場日Feb 26, 2021
最高経営責任者「CEO」Mr. Todd Usen
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし